SGLT2 inhibitor/ja: Difference between revisions
SGLT2 inhibitor/ja
No edit summary |
Created page with "| Tofogliflozin/ja (10 mg) || 97.50% || 83% || 0.75 || 6.8 || 489 ng/mL || 2900 fold |}" |
||
| Line 96: | Line 96: | ||
このクラスの様々な医薬品の[[elimination half-life/ja|消失半減期]]、[[bioavailability/ja|バイオアベイラビリティ]]、[[protein binding/ja|タンパク質結合]]、時間tmaxにおける血中濃度[[Cmax (pharmacology)/ja|Cmax]]、およびその他の[[pharmacokinetic/ja|薬物動態]]パラメータを表2に示す。これらの医薬品は不活性代謝物として尿中に排泄される。 | このクラスの様々な医薬品の[[elimination half-life/ja|消失半減期]]、[[bioavailability/ja|バイオアベイラビリティ]]、[[protein binding/ja|タンパク質結合]]、時間tmaxにおける血中濃度[[Cmax (pharmacology)/ja|Cmax]]、およびその他の[[pharmacokinetic/ja|薬物動態]]パラメータを表2に示す。これらの医薬品は不活性代謝物として尿中に排泄される。 | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ 表2: 様々なSGLT-2阻害剤の薬物動態パラメータ | ||
|- | |- | ||
! | ! 薬物名 !! 生物学的利用能 !! タンパク質結合 !! 最大（時間） !! t1/2 (hours) !! Cmax !! SGLT1に対するSGLT2選択性 | ||
|- | |- | ||
| [[Canagliflozin]] || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold | | [[Canagliflozin/ja]] || 65% (300 mg dose) || 99% || 1–2 || 10.6 (100 mg dose); 13.1 (300 mg dose) || 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) || 250 fold | ||
|- | |- | ||
| [[Dapagliflozin]] || 78% || 91% || 1–1.5 || 12.9 || 79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) || 1200 fold | | [[Dapagliflozin/ja]] || 78% || 91% || 1–1.5 || 12.9 || 79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) || 1200 fold | ||
|- | |- | ||
| [[Empagliflozin]] || 90–97% (mice); 89% (dogs); 31% (rats) || 86.20% || 1.5 || 13.2 (10 mg dose); 13.3h (25 mg dose) || 259nmol/L (10 mg dose); 687nmol/L (25 mg dose) || 2500 fold | | [[Empagliflozin/ja]] || 90–97% (mice); 89% (dogs); 31% (rats) || 86.20% || 1.5 || 13.2 (10 mg dose); 13.3h (25 mg dose) || 259nmol/L (10 mg dose); 687nmol/L (25 mg dose) || 2500 fold | ||
|- | |- | ||
| [[Ertugliflozin]] || 70-90% || 95% || 0.5-1.5 || 11-17 ||268 ng/mL (15 mg dose) || 2000 fold | | [[Ertugliflozin/ja]] || 70-90% || 95% || 0.5-1.5 || 11-17 ||268 ng/mL (15 mg dose) || 2000 fold | ||
|- | |- | ||
| [[Ipragliflozin]] (50 mg) || 90% || 96.30% || 1 || 15–16 (50 mg dose) || 975 ng/mL || 360 fold | | [[Ipragliflozin/ja]] (50 mg) || 90% || 96.30% || 1 || 15–16 (50 mg dose) || 975 ng/mL || 360 fold | ||
|- | |- | ||
| [[Luseogliflozin]] || 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) || 96.0–96.3% || 0.625±0.354 || 9.24±0.928 || 119±27.0 ng/mL || 1650 fold | | [[Luseogliflozin/ja]] || 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) || 96.0–96.3% || 0.625±0.354 || 9.24±0.928 || 119±27.0 ng/mL || 1650 fold | ||
|- | |- | ||
| [[Tofogliflozin/ja]] (10 mg) || 97.50% || 83% || 0.75 || 6.8 || 489 ng/mL || 2900 fold | |||
| [[Tofogliflozin]] (10 mg) || 97.50% || 83% || 0.75 || 6.8 || 489 ng/mL || 2900 fold | |||
|} | |} | ||
<div lang="en" dir="ltr" class="mw-content-ltr"> | <div lang="en" dir="ltr" class="mw-content-ltr"> | ||